A Butyrate Metabolism‐Related Gene Signature Predicts Prognosis, Immune Landscape, and Immunotherapy Efficacy in Breast Cancer
Cancer Medicine · 2026-04 · 15 (4)
DOI: 10.1002/cam4.71763 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 26.03.2026. Verfasst von Xu Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Butyrates, Immunotherapy, Biomarkers, Tumor. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Henan Province, National Natural Science Foundation of China, Key Technologies R & D Program of the Henan Provincial Department of Science and Technology.
Abstract (Originalsprache)
Emerging evidence highlights the critical role of metabolic pathways in breast cancer (BC) progression. Here, we developed a butyrate metabolism‐specific gene (BMRG) signature to predict clinical outcomes and immunotherapy responses in BC, providing a novel pathway‐focused prognostic tool. Using data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), we identified 102 butyrate metabolism‐related differentially expressed genes (DEGs) through the intersection of DEGs, WGCNA‐derived key module genes, and BMRGs. Univariate Cox followed by least absolute shrinkage and selection operator (LASSO) analysis identified nine genes to construct a prognostic signature, which served as an independent prognostic factor. Risk stratification revealed distinct immune microenvironment and mutation landscapes between subgroups, with risk scores strongly correlating with immune checkpoint expression. The signature exhibited robust prognostic performance, with AUC values for 3‐, 5‐, and 7‐year overall survival ranging from 0.65–0.69 in TCGA and 0.57–0.77 in independent GEO cohorts. Protein–protein interaction analysis identified ACSL1 as a key hub gene, and functional validation confirmed that ACSL1 knockdown suppressed BC cell proliferation and migration. Our findings establish this novel nine‐gene butyrate metabolism‐specific signature as a promising prognostic biomarker and potential therapeutic target for BC, providing a metabolism‐focused perspective for personalized BC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
ORCID-Profile: Wenjie Sun, Hong Ge, Nannan Zhang
Förderung
- Natural Science Foundation of Henan Province
- National Natural Science Foundation of China
- Key Technologies R & D Program of the Henan Provincial Department of Science and Technology
- National Science and Technology Major Project of the Ministry of Science and Technology of China
- National Science and Technology Major Project
Zitieren
APA
Wang, X., Zheng, X., Tuo, Z., Sun, W., Li, Y., Ge, H., & Zhang, N. (2026). A Butyrate Metabolism‐Related Gene Signature Predicts Prognosis, Immune Landscape, and Immunotherapy Efficacy in Breast Cancer. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71763
Vancouver
Wang X, Zheng X, Tuo Z, Sun W, Li Y, Ge H, et al. A Butyrate Metabolism‐Related Gene Signature Predicts Prognosis, Immune Landscape, and Immunotherapy Efficacy in Breast Cancer. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71763
BibTeX
@article{Wang2026,
author = {Wang, Xu and Zheng, Xuefeng and Tuo, Zhan and Sun, Wenjie and Li, Yexiong and Ge, Hong and Zhang, Nannan},
title = {A Butyrate Metabolism‐Related Gene Signature Predicts Prognosis, Immune Landscape, and Immunotherapy Efficacy in Breast Cancer},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cam4.71763}
}
EUVIMED